These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 32949266)
21. Mild renal dysfunction defined by creatinine clearance rate has limited impact on clinical outcomes after allogeneic hematopoietic stem cell transplantation. Ikegawa S; Matsuoka KI; Inomata T; Ikeda N; Sugiura H; Kuroi T; Asano T; Yoshida S; Nishimori H; Fujii N; Kondo E; Maeda Y; Tanimoto M Int J Hematol; 2018 May; 107(5):568-577. PubMed ID: 29299798 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients. Ibrahim ME; Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant CL; Bowles DW; George B; Wen X; Buckley B; Aleksunes L; Joy MS Eur J Clin Pharmacol; 2019 Jan; 75(1):51-57. PubMed ID: 30220072 [TBL] [Abstract][Full Text] [Related]
23. Population Model of Serum Creatinine as Time-Dependent Covariate in Neonates. Krzyzanski W; Smits A; Van Den Anker J; Allegaert K AAPS J; 2021 Jun; 23(4):86. PubMed ID: 34142253 [TBL] [Abstract][Full Text] [Related]
24. Estimation of creatinine clearance without 24-hour urine collection--a useful guide during cisplatin therapy. Haim N; Oman SD; Galai N; Burde B; Nathan S; Catane R Acta Oncol; 1993; 32(4):409-12. PubMed ID: 8369128 [TBL] [Abstract][Full Text] [Related]
25. Alterations in Cisplatin Pharmacokinetics and Its Acute/Sub-chronic Kidney Injury over Multiple Cycles of Cisplatin Treatment in Rats. Okada A; Fukushima K; Fujita M; Nakanishi M; Hamori M; Nishimura A; Shibata N; Sugioka N Biol Pharm Bull; 2017; 40(11):1948-1955. PubMed ID: 29093343 [TBL] [Abstract][Full Text] [Related]
26. [Serum creatinine and creatinine clearance to estimate renal function in essential hypertension]. Jabary NS; Martín D; Muñoz MF; Santos M; Herruzo J; Gordillo R; Bustamante J Nefrologia; 2006; 26(1):64-73. PubMed ID: 16649427 [TBL] [Abstract][Full Text] [Related]
27. Renal function in the oldest-old on an acute geriatric ward. Van den Noortgate NJ; Janssens WH; Afschrift MB; Lameire NH Int Urol Nephrol; 2001; 32(4):531-7. PubMed ID: 11989541 [TBL] [Abstract][Full Text] [Related]
28. Renal tolerance of cisplatin in patients more than 80 years old. Thyss A; Saudes L; Otto J; Creisson A; Gaspard MH; Dassonville O; Schneider M J Clin Oncol; 1994 Oct; 12(10):2121-5. PubMed ID: 7931482 [TBL] [Abstract][Full Text] [Related]
29. Renal responses to atrial natriuretic peptide (ANP) in rats with non-oliguric acute renal failure induced by cisplatin. Nagano N; Yagi M; Kato S; Furuya Y; Miyata S; Manabe N J Vet Med Sci; 1995 Dec; 57(6):997-1002. PubMed ID: 8720036 [TBL] [Abstract][Full Text] [Related]
30. Comparison of the Cockcroft-Gault, MDRD and CKD-EPI equations for estimating ganciclovir clearance. Palacio-Lacambra ME; Comas-Reixach I; Blanco-Grau A; Suñé-Negre JM; Segarra-Medrano A; Montoro-Ronsano JB Br J Clin Pharmacol; 2018 Sep; 84(9):2120-2128. PubMed ID: 29791023 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Gretler DD; Guerciolini R; Williams PJ Clin Ther; 2004 Mar; 26(3):390-8. PubMed ID: 15110131 [TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Urien S; Lokiec F Br J Clin Pharmacol; 2004 Jun; 57(6):756-63. PubMed ID: 15151521 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function. Brier ME; Gaylor SK; McGovren JP; Glue P; Fang A; Aronoff GR J Clin Pharmacol; 2011 May; 51(5):731-8. PubMed ID: 20484616 [TBL] [Abstract][Full Text] [Related]
34. A comparative study of uranyl nitrate and cisplatin-induced renal failure in rat. Mahmood I; Waters DH Eur J Drug Metab Pharmacokinet; 1994; 19(4):327-36. PubMed ID: 7737234 [TBL] [Abstract][Full Text] [Related]
35. Serial-measured versus estimated creatinine clearance in patients with non-small cell lung cancer receiving cisplatin-based chemotherapy. Chang GC; Yang TY; Shih CM; Lin LY; Lee HS; Chiang CD J Formos Med Assoc; 2003 Apr; 102(4):257-61. PubMed ID: 12833190 [TBL] [Abstract][Full Text] [Related]
36. Implications of serum creatinine measurements on GFR estimation and vancomycin dosing in children. Neuman G; Nulman I; Adeli K; Koren G; Colantonio DA; Helldén A J Clin Pharmacol; 2014 Jul; 54(7):785-91. PubMed ID: 24596064 [TBL] [Abstract][Full Text] [Related]
37. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin. Zhang JS; Imai T; Otagiri M Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675 [TBL] [Abstract][Full Text] [Related]
38. Can pre-liver transplantation renal insufficiency using a creatinine clearance calculator predict long-term survival? Boin IF; de Ataide EC; Dias EP; Stucchi RS; Seva-Pereira T; Calomeni G; Capel Junior CC; Mazzali M Transplant Proc; 2012 Oct; 44(8):2452-4. PubMed ID: 23026618 [TBL] [Abstract][Full Text] [Related]
39. Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis. Hodiamont CJ; Juffermans NP; Bouman CS; de Jong MD; Mathôt RA; van Hest RM Int J Antimicrob Agents; 2017 Feb; 49(2):204-211. PubMed ID: 28038961 [TBL] [Abstract][Full Text] [Related]
40. Occult renal impairment is common in patients with peripheral vascular disease and normal serum creatinine. Rashid ST; Salman M; Agarwal S; Hamilton G Eur J Vasc Endovasc Surg; 2006 Sep; 32(3):294-9. PubMed ID: 16716614 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]